Atrasentan received FDA approval for IgA nephropathy, reducing proteinuria by 36% and showing consistent efficacy across diverse patient groups. Value-based care programs significantly slowed CKD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results